A Multicenter, Randomized, Open-label, Controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of CAN008 Combined With Re-irradiation (rRT) for Treating Patients With Recurrent Glioblastoma (GBM)
Status: Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 26 Aug 2019
Price : $35 *
At a glance
- Drugs Asunercept (Primary)
- Indications Glioblastoma
- Focus Therapeutic Use
- Sponsors CANbridge Pharmaceuticals
- 26 Aug 2019 According to the CANbridge Pharmaceuticals website, the company was formerly called as CANbridge Life Sciences.
- 15 Nov 2018 Status changed from planning to not yet recruiting.
- 17 Apr 2018 New trial record